Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis’s failure in osteoporosis could be bad break for Tarsa

This article was originally published in Scrip

Executive Summary

Novartis’s SMC021 failed to meet main fracture reduction endpoints in osteoporosis Phase III trial. While the result is arguably unsurprising for a calcitonin candidate, it is a setback for other companies such as Tarsa Therapeutics aiming to stimulate growth of the class. Tarsa may now struggle to secure a partner willing to bring its pipeline drug Ostora to the market. Novartis is expected to discontinue development of SMC021 and focus on more attractive targets for osteoporosis treatment.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts